{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:11:25Z","timestamp":1789819885840,"version":"4.0.1"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019687","name":"Hamad Bin Khalifa University","doi-asserted-by":"publisher","award":["VPR-TG01-007"],"award-info":[{"award-number":["VPR-TG01-007"]}],"id":[{"id":"10.13039\/100019687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Anti-COVID19 drugs, such as nirmatrelvir, have been developed targeting the SARS-CoV-2 main protease, M<jats:sup>pro<\/jats:sup>, based on the critical requirement of its proteolytic processing of the viral polyproteins into functional proteins essential for viral replication. However, the emergence of SARS-CoV-2 variants with M<jats:sup>pro<\/jats:sup> mutations has raised the possibility of developing resistance against these drugs, likely due to therapeutic targeting of the M<jats:sup>pro<\/jats:sup> catalytic site. An alternative to these drugs is the development of drugs that target an allosteric site distant from the catalytic site in the protein that may reduce the chance of the emergence of resistant mutants. Here, we combine computational analysis with <jats:italic>in vitro<\/jats:italic> assay and report the discovery of a potential allosteric site and an allosteric inhibitor of SARS-CoV-2 M<jats:sup>pro<\/jats:sup>. Specifically, we identified an M<jats:sup>pro<\/jats:sup> metastable state with a deformed catalytic site harboring potential allosteric sites, raising the possibility that stabilization of this metastable state through ligand binding can lead to the inhibition of M<jats:sup>pro<\/jats:sup> activity. We then performed a computational screening of a library (\u223c4.2 million) of drug-like compounds from the ZINC database and identified several candidate molecules with high predicted binding affinity. MD simulations showed stable binding of the three top-ranking compounds to the putative allosteric sites in the protein. Finally, we tested the three compounds <jats:italic>in vitro<\/jats:italic> using a BRET-based M<jats:sup>pro<\/jats:sup> biosensor and found that one of the compounds (ZINC4497834) inhibited the M<jats:sup>pro<\/jats:sup> activity. We envisage that the identification of a potential allosteric inhibitor of M<jats:sup>pro<\/jats:sup> will aid in developing improved anti-COVID-19 therapy.<\/jats:p>","DOI":"10.3389\/fmolb.2024.1451280","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:00:06Z","timestamp":1725616806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A potential allosteric inhibitor of SARS-CoV-2 main protease (Mpro) identified through metastable state analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Asma","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya M.","family":"Geethakumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam S.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir H.","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.846996","article-title":"Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike: ACE2 complex","volume":"506","author":"Ahmed","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"131864","DOI":"10.1016\/j.ijbiomac.2024.131864","article-title":"A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity","volume":"269","author":"Ahmed","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/ijms22020677","article-title":"Intracellular ionic strength sensing using NanoLuc","volume":"22","author":"Altamash","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2147\/dddt.S370574","article-title":"Allosteric binding sites of the SARS-CoV-2 main protease: potential targets for broad-spectrum anti-coronavirus agents","volume":"16","author":"Alzyoud","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1039\/d0sc06195f","article-title":"Mechanism of inhibition of SARS-CoV-2 M(pro) by N3 peptidyl Michael acceptor explained by QM\/MM simulations and design of new derivatives with tunable chemical reactivity","volume":"12","author":"Arafet","year":"2020","journal-title":"Chem. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2208525120","DOI":"10.1073\/pnas.2208525120","article-title":"SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression","volume":"120","author":"Arshad","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"102768","DOI":"10.1016\/j.sbi.2023.102768","article-title":"Protein dynamics underlying allosteric regulation","volume":"84","author":"Astore","year":"2024","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1080\/07391102.2021.1891141","article-title":"Targeting allosteric pockets of SARS-CoV-2 main protease Mpro","volume":"40","author":"Bhat","year":"","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1080\/07391102.2021.1891141","article-title":"Targeting allosteric pockets of SARS-CoV-2 main protease M(pro)","volume":"40","author":"Bhat","year":"","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B10","doi-asserted-by":"publisher","first-page":"130077","DOI":"10.1016\/j.ijbiomac.2024.130077","article-title":"MD simulations indicate Omicron P132H of SARS-CoV-2 M(pro) is a potential allosteric mutant involved in modulating the dynamics of catalytic site entry loop","volume":"262","author":"Bhat","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14760584.2021.1903879","article-title":"Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev. vaccines."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1021\/bi702025w","article-title":"The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP","volume":"47","author":"Biswas","year":"","journal-title":"Biochemistry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e882","DOI":"10.7717\/peerj.882","article-title":"Cyclic nucleotide binding and structural changes in the isolated GAF domain of Anabaena adenylyl cyclase, CyaB2","volume":"3","author":"Biswas","year":"2015","journal-title":"PeerJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12045-017-0431-z","article-title":"Allosteric regulation of proteins: A historical perspective on the development of concepts and techniques","volume":"22","author":"Biswas","year":"2017","journal-title":"Resonance"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1021\/bi702025w","article-title":"The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP","volume":"47","author":"Biswas","year":"","journal-title":"Biochemistry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1074\/jbc.M110.193185","article-title":"Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions","volume":"286","author":"Biswas","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/bioinformatics\/btx349","article-title":"MD-TASK: a software suite for analyzing molecular dynamics trajectories","volume":"33","author":"Brown","year":"2017","journal-title":"Bioinformatics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/d41586-022-01771-3","article-title":"Fast-evolving COVID variants complicate vaccine updates","volume":"607","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1021\/acs.jpclett.0c03182","article-title":"Candidate binding sites for allosteric inhibition of the SARS-CoV-2 main protease from the analysis of large-scale molecular dynamics simulations","volume":"12","author":"Carli","year":"2021","journal-title":"J. Phys. Chem. Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"m3862","DOI":"10.1136\/bmj.m3862","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"371","author":"Cevik","year":"2020","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"13686","DOI":"10.1039\/D1SC03628A","article-title":"Discovery of SARS-CoV-2 Mpro peptide inhibitors from modelling substrate and ligand binding","volume":"12","author":"Chan","year":"2021","journal-title":"Chem. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/cid\/ciab656","article-title":"Impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant-associated receptor binding domain (RBD) mutations on the susceptibility to serum antibodies elicited by coronavirus disease 2019 (COVID-19) infection or vaccination","volume":"74","author":"Chen","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1021\/acscentsci.3c00054","article-title":"SARS-CoV-2 Mpro protease variants of concern display altered viral substrate and cell host target galectin-8 processing but retain sensitivity toward antivirals","volume":"9","author":"Chen","year":"2023","journal-title":"ACS Central Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.csbj.2023.02.020","article-title":"In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases","volume":"21","author":"Cheohen","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14756366.2020.1850710","article-title":"Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors","volume":"36","author":"Chiou","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41586-023-06634-z","article-title":"The burden and dynamics of hospital-acquired SARS-CoV-2 in England","volume":"623","author":"Cooper","year":"2023","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1063\/1.470648","article-title":"Constant pressure molecular dynamics simulation: the Langevin piston method","volume":"103","author":"Feller","year":"1995","journal-title":"J. Chem. Phys."},{"key":"B32","doi-asserted-by":"publisher","first-page":"102023","DOI":"10.1016\/j.jbc.2022.102023","article-title":"Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2","volume":"298","author":"Ferreira","year":"2022","journal-title":"J. Biol. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"692168","DOI":"10.3389\/fchem.2021.692168","article-title":"Catalytic dyad residues His41 and Cys145 impact the catalytic activity and overall conformational fold of the main SARS-CoV-2 protease 3-chymotrypsin-like protease","volume":"9","author":"Ferreira","year":"2021","journal-title":"Front. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e77433","DOI":"10.7554\/eLife.77433","article-title":"Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms","volume":"11","author":"Flynn","year":"2022","journal-title":"eLife"},{"key":"B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.slasd.2022.01.001","article-title":"Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection","volume":"27","author":"Ge","year":"2022","journal-title":"SLAS Discov."},{"key":"B36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s42004-022-00731-2","article-title":"A genetically encoded BRET-based SARS-CoV-2 M(pro) protease activity sensor","volume":"5","author":"Geethakumari","year":"","journal-title":"Commun. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"478460","DOI":"10.1101\/2022.01.31.478460","article-title":"A Genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor","author":"Geethakumari","year":"","journal-title":"bioRxiv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e149187","DOI":"10.1172\/jci.insight.149187","article-title":"SARS-CoV-2 vaccines: a triumph of science and collaboration","volume":"6","author":"Golob","year":"2021","journal-title":"JCI insight"},{"key":"B39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.virusres.2007.02.015","article-title":"Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery","volume":"133","author":"Grum-Tokars","year":"2008","journal-title":"Virus Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 transmission and pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (Mpro): structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat. methods"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e28786","DOI":"10.1002\/jmv.28786","article-title":"COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: differences between vaccine subtypes. A multicontinental cohort study","volume":"95","author":"Huespe","year":"2023","journal-title":"J. Med. Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1021\/acs.jmedchem.1c00566","article-title":"Discovery and mechanism of SARS-CoV-2 main protease inhibitors","volume":"65","author":"Huff","year":"2022","journal-title":"J. Med. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"B48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC--a free database of commercially available compounds for virtual screening","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model"},{"key":"B49","volume-title":"Global economic effects of COVID-19","author":"Jackson","year":"2022"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2233637","article-title":"Identification of a potential DNA methyltransferase (DNMT) inhibitor","author":"Jan","year":"","journal-title":"J. Biomol. Struct. and Dyn."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1016\/j.csbj.2023.07.020","article-title":"Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease Mpro","volume":"21","author":"Jan","year":"","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/s2666-5247(21)00068-9","article-title":"SARS-CoV-2 spike E484K mutation reduces antibody neutralisation","volume":"2","author":"Jangra","year":"2021","journal-title":"Lancet Microbe"},{"key":"B53","doi-asserted-by":"publisher","first-page":"15452","DOI":"10.1038\/s41598-021-94951-6","article-title":"Comprehensive virtual screening of 4.8 k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 M(PRO)","volume":"11","author":"Jim\u00e9nez-Avalos","year":"2021","journal-title":"Sci. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1016\/j.csbj.2022.06.023","article-title":"Maturation of the SARS-CoV-2 virus is regulated by dimerization of its main protease","volume":"20","author":"Kaptan","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"570927","DOI":"10.3389\/fimmu.2020.570927","article-title":"SARS-CoV-2: pathogenesis, and advancements in diagnostics and treatment","volume":"11","author":"Khalaf","year":"2020","journal-title":"Front. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc. Chem. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-CoV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1038\/s41467-022-32854-4","article-title":"X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101739","DOI":"10.1016\/j.jbc.2022.101739","article-title":"Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate","volume":"298","author":"Legare","year":"2022","journal-title":"J. Biol. Chem."},{"key":"B64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1109\/CIBCB.2012.6217214","volume-title":"2012 IEEE symposium on computational intelligence in bioinformatics and computational biology (CIBCB)","author":"Li","year":"2012"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1093\/bioinformatics\/btw215","article-title":"CaFE: a tool for binding affinity prediction using end-point free energy methods","volume":"32","author":"Liu","year":"2016","journal-title":"Bioinforma. Oxf. Engl."},{"key":"B67","doi-asserted-by":"publisher","first-page":"852210","DOI":"10.3389\/fchem.2022.852210","article-title":"Crystallization of feline coronavirus Mpro with GC376 reveals mechanism of inhibition","volume":"10","author":"Lu","year":"2022","journal-title":"Front. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41401-022-00929-z","article-title":"Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376","volume":"44","author":"Luan","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"B69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1213\/ANE.0000000000004845","article-title":"Coronaviruses and SARS-CoV-2: a brief overview","volume":"131","author":"Ludwig","year":"2020","journal-title":"Anesth. analgesia"},{"key":"B70","doi-asserted-by":"publisher","first-page":"105672","DOI":"10.1016\/j.jbc.2024.105672","article-title":"What is allosteric regulation? Exploring the exceptions that prove the rule","volume":"300","author":"McCullagh","year":"2024","journal-title":"J. Biol. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0297921","DOI":"10.1128\/mbio.02979-21","article-title":"The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines","volume":"13","author":"McLean","year":"2022","journal-title":"mBio"},{"key":"B72","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1038\/s41467-023-41312-8","article-title":"Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets","volume":"14","author":"Mihalic","year":"2023","journal-title":"Nat. Commun."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0952-y","article-title":"Disease and healthcare burden of COVID-19 in the United States","author":"Miller","year":"2020","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"809244","DOI":"10.3389\/fimmu.2021.809244","article-title":"SARS-CoV-2 variants, vaccines, and host immunity","volume":"12","author":"Mistry","year":"2022","journal-title":"Front. Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3390\/biom12121754","article-title":"Structure-based virtual screening and functional validation of potential hit molecules targeting the SARS-CoV-2 main protease","volume":"12","author":"Moovarkumudalvan","year":"2022","journal-title":"Biomolecules"},{"key":"B76","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Commun. Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"103004","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease","volume":"299","author":"Noske","year":"2023","journal-title":"J. Biol. Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.3390\/ijms24076062","article-title":"Stabilization of the dimeric state of SARS-CoV-2 main protease by GC376 and nirmatrelvir","volume":"24","author":"Paciaroni","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"115491","DOI":"10.1016\/j.ejmech.2023.115491","article-title":"The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022","volume":"257","author":"Pang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11224-022-02089-6","article-title":"Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by Molecular Dynamics Simulations","author":"Parmar","year":"2022","journal-title":"Struct. Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1039\/d0sc04942e","article-title":"Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease","volume":"12","author":"Pavlova","year":"2021","journal-title":"Chem. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.csbj.2023.02.019","article-title":"Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2","volume":"21","author":"Philip","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Puhl","year":"2019","journal-title":"Nat. Mater."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e1004586","DOI":"10.1371\/journal.pcbi.1004586","article-title":"AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility","volume":"11","author":"Ravindranath","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"103670","DOI":"10.1016\/j.compbiomed.2020.103670","article-title":"Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus","volume":"119","author":"Robson","year":"2020","journal-title":"Comput. Biol. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/s41598-022-06306-4","article-title":"Non-covalent SARS-CoV-2 M(pro) inhibitors developed from in silico screen hits","volume":"12","author":"Rossetti","year":"2022","journal-title":"Sci. Rep."},{"key":"B89","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/1568026620666201207095117","article-title":"An updated review on SARS-CoV-2 main proteinase (M(pro)): protein structure and small-molecule inhibitors","volume":"21","author":"Sabbah","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","volume":"369","author":"Salje","year":"2020","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","first-page":"105381","DOI":"10.1016\/j.antiviral.2022.105381","article-title":"Allosteric inhibitors of the main protease of SARS-CoV-2","volume":"205","author":"Samrat","year":"2022","journal-title":"Antivir. Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.addr.2020.11.007","article-title":"Peptide and peptide-based inhibitors of SARS-CoV-2 entry","volume":"167","author":"Sch\u00fctz","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"B94","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.amsu.2020.12.030","article-title":"Protease inhibitor GC376 for COVID-19: lessons learned from feline infectious peritonitis","volume":"61","author":"Sharun","year":"2021","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1810778","article-title":"Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study","volume":"40","author":"Shree","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B96","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/jcc.540150702","article-title":"New spherical\u2010cutoff methods for long\u2010range forces in macromolecular simulation","volume":"15","author":"Steinbach","year":"1994","journal-title":"J. Comput. Chem."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15--ligand discovery for everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model"},{"key":"B98","doi-asserted-by":"publisher","first-page":"167748","DOI":"10.1016\/j.jmb.2022.167748","article-title":"Allosteric hotspots in the main protease of SARS-CoV-2","volume":"434","author":"Str\u00f6mich","year":"2022","journal-title":"J. Mol. Biol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e2120913119","DOI":"10.1073\/pnas.2120913119","article-title":"An extended conformation of SARS-CoV-2 main protease reveals allosteric targets","volume":"119","author":"Sun","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"","journal-title":"Nat. Rev. Genet."},{"key":"B101","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"","journal-title":"Nat. Rev. Genet."},{"key":"B102","doi-asserted-by":"publisher","first-page":"14098","DOI":"10.1039\/d1sc03526f","article-title":"Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate","volume":"12","author":"Tao","year":"","journal-title":"Chem. Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"102758","DOI":"10.1016\/j.sbi.2023.102758","article-title":"Allosteric drugs: new principles and design approaches","volume":"84","author":"Tee","year":"2024","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","article-title":"Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications","volume":"28","author":"Trougakos","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"106449","DOI":"10.1016\/j.compbiomed.2022.106449","article-title":"SARS-CoV-2 proteases Mpro and PLpro: design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations","volume":"153","author":"Tumskiy","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s42247-024-00663-8","article-title":"Engineering \u03b2-catenin-derived peptides for \u03b1-catenin binding","author":"Uddin","year":"2024","journal-title":"Emergent Mater."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.vaccine.2022.02.047","article-title":"The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals","volume":"40","author":"Uwamino","year":"2022","journal-title":"Vaccine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13205-020-02630-6","article-title":"Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis","volume":"11","author":"Verma","year":"2021","journal-title":"3 Biotech."},{"key":"B110","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/13543776.2021.1880568","article-title":"SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19","volume":"31","author":"Vicenti","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"B111","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1021\/ci100241y","article-title":"Analyzing the topology of active sites: on the prediction of pockets and subpockets","volume":"50","author":"Volkamer","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1093\/bioinformatics\/bts310","article-title":"DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment","volume":"28","author":"Volkamer","year":"2012","journal-title":"Bioinformatics"},{"key":"B114","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-pharmtox-010611-134525","article-title":"Drugs for allosteric sites on receptors","volume":"54","author":"Wenthur","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B115","unstructured":"The PyMOL molecular graphics system\n            WlD.\n          2002"},{"key":"B116","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijid.2020.03.004","article-title":"The SARS-CoV-2 outbreak: What we know","volume":"94","author":"Wu","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B117","doi-asserted-by":"publisher","first-page":"102737","DOI":"10.1016\/j.sbi.2023.102737","article-title":"Allosteric communication and signal transduction in proteins","volume":"84","author":"Wu","year":"2024","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/jvi.02114-07","article-title":"Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design","volume":"82","author":"Xue","year":"2008","journal-title":"J. Virol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e1298","DOI":"10.1002\/wcms.1298","article-title":"Using PyMOL as a platform for computational drug design","volume":"7","author":"Yuan","year":"2017","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/prot.26164","article-title":"Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease","volume":"89","author":"Yuce","year":"2021","journal-title":"Proteins"},{"key":"B121","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2024.1451280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:00:24Z","timestamp":1725616824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2024.1451280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":118,"alternative-id":["10.3389\/fmolb.2024.1451280"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2024.1451280","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"article-number":"1451280"}}